secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001564590-22-006755
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera FY2021 revenue $375M (+61% YoY); EPS $0.56; 26 new program starts
---------------------------------------------------------------------------

- Total revenue $375.2M (up 61% from $233.2M in 2020), driven by $327.3M in royalty revenue.
- Net earnings $153.5M ($0.56 basic EPS) vs. $118.9M ($0.53) in 2020; diluted EPS $0.48.
- Ended year with $723M in cash and marketable securities; 26 new program starts (78 cumulative).
- Q4 revenue $139.3M (37% of FY total), net earnings $59.9M ($0.21 basic EPS).
- Five molecules now in clinic (up from one); acquired TetraGenetics for transmembrane protein targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022006755/0001564590-22-006755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022006755/abcl-8k_20220224.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-006755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer